ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Regeneron Pharmaceuticals and BioNTech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Regeneron PharmaceuticalsBioNTech
studies on the registry414125
open to participants now8433
phase 3 studies under way389
reach primary completion within a year3011
programswith a study of their own in two years4424

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseRegeneron PharmaceuticalsBioNTech
Phase 1

Regeneron Pharmaceuticals: 9 of its 44 programs at phase 1

  1. REGN9533phase 1
  2. ALN-SNCAphase 1
  3. REGN17235phase 1
  4. REGN20423phase 1
  5. REGN20566phase 1

and 4 more — sign in to see them all

20%

BioNTech: 4 of its 24 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%
Phase 2

Regeneron Pharmaceuticals: 16 of its 44 programs at phase 2

  1. ALN-PNPphase 2
  2. vonsetamigphase 2
  3. ALN-ANG3phase 2
  4. olsutamigphase 2
  5. ubamatamabphase 2

and 11 more — sign in to see them all

36%
67%
Phase 3

Regeneron Pharmaceuticals: 15 of its 44 programs at phase 3

  1. cemiplimabphase 3
  2. cenvacibartphase 3
  3. fianlimabphase 3
  4. odronextamabphase 3
  5. amrecibartphase 3

and 10 more — sign in to see them all

34%

BioNTech: 3 of its 24 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%
Approved, new studies

Regeneron Pharmaceuticals: 4 of its 44 programs at approved, new studies

  1. linvoseltamabapproved, new study
  2. pozelimabapproved, new study
  3. dupilumabapproved, new study
  4. alirocumabapproved, new study
9%

BioNTech: 1 of its 24 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Regeneron Pharmaceuticals14 readouts · 4 phase 3·

Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion

  1. ALN-ANG3phase 2 · Dec 4 · NCT06452771
  2. alirocumabapproved, new study · Dec 29 · NCT07477704

Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fianlimabphase 3 · Jan 15 · NCT05608291

Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion

  1. REGN22044phase 1 · Feb 8 · NCT07526116
  2. amrecibartphase 3 · Feb 9 · NCT07175428
  3. cenvacibartphase 3 · Feb 9 · NCT07175428
  4. REGN20934phase 1 · Feb 22 · NCT07594093

Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cemiplimabphase 3 · Mar 22 · NCT06246916

Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. REGN9533phase 1 · Apr 2 · NCT07759167
  2. dupilumabapproved, new study · Apr 24 · NCT06572228
·

Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mibavademabphase 3 · Jun 18 · NCT07220772
·

Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion

  1. ALN-PNPphase 2 · Aug 10 · NCT05648214
  2. ALN-CIDEBphase 3 · Aug 17 · NCT06836609
  3. linvoseltamabapproved, new study · Aug 31 · NCT06369467
··
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Regeneron Pharmaceuticals

New programs 6

  • REGN20566phase 1 · first study · Nov 13 · Obesity
  • REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
  • REGN13089phase 2 · first study · Oct 2
  • REGN24493phase 1 · first study · Sep 30 · Graves Disease
  • REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
  • ALN-6457phase 2 · first study · Sep 16 · Dementia

Reached a new phase 2

Study stopped 0

None

Primary completion later 6

BioNTech

New programs 3

  • BNT3211phase 2 · first study · Nov 16
  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionRegeneron PharmaceuticalsBioNTech
Carcinoma, Non-Small-Cell Lungboth · compare here

Regeneron Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3
  3. ubamatamabphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

BioNTech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. pumitamigphase 3
  2. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsboth · compare here

Regeneron Pharmaceuticals in Prostatic Neoplasms: 2 programs

  1. olsutamigphase 2
  2. REGN21353phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Prostatic Neoplasms in search

BioNTech in Prostatic Neoplasms: 1 program

  1. Elfetabart Drozuntecanphase 3

Their studies: BioNTech’s studies of Prostatic Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Regeneron Pharmaceuticals 17 of 44 · BioNTech 11 of 24 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.